Summit Healthcare Acquisition Corp - Ordinary Shares - Class A

NASDAQ:SMIH  
10.00
+0.01 (+0.10%)
Mergers / Acquisitions

YS Biopharma To Merge With Nasdaq-Listed Summit Healthcare Acquisition Corp

Published: 09/29/2022 20:16 GMT
Summit Healthcare Acquisition Corp - Ordinary Shares - Class A (SMIH) - Ys Biopharma to Merge With Nasdaq-listed Summit Healthcare Acquisition Corp.
Summit Healthcare Acquisition Corp - Transaction Values Ys Biopharma at Pre-money Equity Value of $834 Millio.
Summit Healthcare Acquisition Corp - Upon Closing, Combined Co Will Be Renamed As Ys Biopharma Co.
, Ltd.
, Become Publicly Traded Co on Nasdaq.
Summit Healthcare Acquisition Corp - Ys Biopharma Shareholders Will Become Majority Owners Immediately After Closing of Transaction.
Summit Healthcare Acquisition Corp - Business Combination is Expected to Provide Up to Approximately $230 Million in Gross Proceeds to Ys Biopharma.
Summit Healthcare Acquisition Corp- Upon Closing, Ys Biopharma Will Continue to Be Led by Mr. Yi Zhang, Dr.
Hui Shao, and Current Management Team.
Summit Healthcare Acquisition Corp - Transaction is Targeted to Be Completed in Q1 of 2023.